🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This is an open-label, multi-center, randomized, phase III study. It is aim...
Status
Active Not Recruiting
Location
Guangdong Lung cancer institute
Start Date
2022-06-20
Trial ID
NCT04841811
Treatments Being Tested
According to literature reports, about 16.3%-19% of newly diagnosed NSCLC p...
Status
Unknown
Location
Chongqing University Cancer Hospital
Start Date
2021-03-01
Trial ID
NCT04905550
Aumolertinib is a third-generation epidermal growth factor receptor (EGFR) ...
Status
Terminated
Location
Highlands Oncology Group
Start Date
2022-12-14
Trial ID
NCT05493501
This study is conducted to determine the safety, tolerability, pharmacokine...
Status
Unknown
Location
Shanghai Chest Hospital
Start Date
2022-01-05
Trial ID
NCT05430386
Treatments Being Tested
HS-10241, an oral and highly selective MET-TKI, may contribute to overcomin...
Status
Unknown
Location
Multiple Locations
Start Date
2023-12-30
Trial ID
NCT06110663
Treatments Being Tested
The goal of this clinical trial is to test in Locally Advanced or Metastati...
Status
Unknown
Location
Zhongshan hospital
Start Date
2024-06
Trial ID
NCT06463171
Treatments Being Tested
To assess the efficacy and safety of Almonertinib versus platinum-based che...
Status
Unknown
Location
Sun yat-sen Univerisity Cancer Center
Start Date
2021-07-15
Trial ID
NCT04951648
Treatments Being Tested
The goal of this observational study is to extract the imaging features of ...
Status
Recruiting
Location
Shanghai Cancer center
Start Date
2024-09-30
Trial ID
NCT06604689
Treatments Being Tested
The goal of this observational study is to explore the feasibility of stere...
Status
Completed
Location
Wuhan Tongji Hospital
Start Date
2018-09-01
Trial ID
NCT06613633
Treatments Being Tested
Almonertinib, as a third-generation EGFR-TKI, has been used for the treatme...
Status
Unknown
Location
Xin Ye
Start Date
2022-01-01
Trial ID
NCT04755738
Treatments Being Tested